Osmotica Pharma has got notice of final approval for its venlafaxine hydrochloride extended-release 37.5 mg, 75 mg, 150 mg and 225 mg tablets NDA from USFDA for major depressive disorder. The Osmotica formulation provides a controlled release tablet form of venlafaxine HCl including a previously unavailable 225 mg dosage strength. Equal doses of venlafaxine HCl Extended-release tablets are bioequivalent to Effexor XR capsules, a leading product marketed by Wyeth, when administered under fed conditions. Osmotica expects to launch the new product line for the two FDA-approved indications in the near future.
Osmotica Pharmaceutical is specializing in neurology based drug therapies and delivery technologies. The Osmotica Group has a portfolio of products in various stages of development focused in the treatment of Parkinson's disease.
Osmotica Pharmaceutical is specializing in neurology based drug therapies and delivery technologies. The Osmotica Group has a portfolio of products in various stages of development focused in the treatment of Parkinson's disease.
